To evaluate the glycemic variations during acute coronary syndrome in non-diabetic patients (euglycemic, or with impaired fasting glucose, or with impaired glucose tolerance)
All nondiabetic patients with dysglycemia (fasting plasma glucose between 100 and 125 mg/dl) will be monitored with a device (Continuous Glucose Monitoring System) and all these patients will be undergone an oral glucose tolerance test after the discharge from this Unit.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
196
This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
Giuseppe Derosa
Pavia, Italy
Glycemic status
Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient. Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus.
Time frame: 15 days
Lipid profile
Total cholesterol
Time frame: 15 days
Lipid profile
HDL-cholesterol
Time frame: 15 days
Lipid profile
Triglycerides
Time frame: 15 days
Lipid profile
Lipoprotein (a)
Time frame: 15 days
Endothelial damage
sICAM-1
Time frame: 15 days
Endothelial damage
sVCAM-1
Time frame: 15 days
Inflammation parameters
sRAGE
Time frame: 15 days
Inflammation parameters
sCD40L
Time frame: 15 days
Inflammation parameters
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MPO
Time frame: 15 days
Inflammation parameters
hs-CRP
Time frame: 15 days
Inflammation parameters
IL-6
Time frame: 15 days
Inflammation parameters
TNF-alfa
Time frame: 15 days
Heart damage
CPK
Time frame: 15 days
Heart damage
I troponin
Time frame: 15 days